Allan E. Rubenstein, MD - President and Chief Executive Officer
Allan E. Rubenstein, MD is Clinical Professor of Neurology and Pediatrics at NYU Langone Medical Center, New York. Dr. Rubenstein has spent most of his career in research on neurofibromatosis (NF) and related genetic disorders. Dr. Rubenstein founded the National NF Foundation (now Children's Tumor Foundation) in 1978, and from 1978 until 2003 he served as its Director of Medical Affairs. Currently he serves as Medical Director Emeritus. Dr. Rubenstein has authored several books on NF and has been a consultant to the NIH, FDA Orphan Drugs Program and the U.S. Department of Defense NF Research Program, where, from 2001 to 2002, he was Chairman of its Integration Panel. Since 1992 Dr. Rubenstein has served as Chairman and subsequently as Vice-Chairman and lead director of the Board of Directors of The Cooper Companies (COO, NYSE), a medical device company. He was also a member from 2000-2003 of the Board of Directors of Bioimaging Technologies (BITI, NASDAQ), a clinical research organization.
Ruihong Chen, PhD - Director of Preclinical Research & Development
Ruihong Chen, PhD joined NexGenix in September 2003. Prior to that, she was a senior scientist at Exelixis Inc. where she was involved in the discovery of novel oncology drugs, with a focus on protein chemistry of various drug targets. From 1996 to 2000, Dr. Chen was a postdoctoral fellow and then an assistant biochemist in Dr. Frank McCormick's laboratory at the UCSF Comprehensive Cancer Center. Prior to that, she was a postdoctoral scientist with Dr. Dafna Bar-Sagi at the State University of New York at Stony Brook. Dr. Chen received her graduate training in Dr. Joseph Lipsick's laboratory at the University of New York at Stony Brook, where she received her Ph.D. degree in molecular genetics and microbiology in 1994. Dr. Chen has over 15 years of research experience in molecular oncology, and has authored many peer reviewed research papers and patents in this field.
Back to top